<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00691197</url>
  </required_header>
  <id_info>
    <org_study_id>AG9689-002</org_study_id>
    <nct_id>NCT00691197</nct_id>
  </id_info>
  <brief_title>Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear</brief_title>
  <official_title>Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Testing the Safety and Acceptability of Using a Rewetting Drop with Contact Lenses
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>Change from Baseline at Day 90</time_frame>
    <description>Percentage of Subjects Tabulated by Changes in Line Number at Day 90 from Baseline; Visual Acuity measured by LogMar reported as Snellen equivalents. Better: an increase of 2 lines or more in at least one eye; No Change: a change less than +/- 2 lines in both eyes; Worse: a decrease of 2 lines or more in at least one eye.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal Staining</measure>
    <time_frame>Day 90</time_frame>
    <description>Corneal staining of greater or equal to grade 2 at day 90. Grading scale: 0 = None Present; 1 = Trace Finding; 2 = Mild Finding; 3 = Moderate Finding; 4 = Severe Finding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">246</enrollment>
  <condition>Ametropia</condition>
  <arm_group>
    <arm_group_label>Carboxymethylcellulose sodium and Glycerin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboxymethylcellulose sodium and Glycerin based rewetting drop</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carboxymethylcellulose sodium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboxymethylcellulose sodium based rewetting drop</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Carboxymethylcellulose sodium and Glycerin</intervention_name>
    <description>Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.</description>
    <arm_group_label>Carboxymethylcellulose sodium and Glycerin</arm_group_label>
    <other_name>Optive™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Carboxymethylcellulose sodium</intervention_name>
    <description>Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.</description>
    <arm_group_label>Carboxymethylcellulose sodium</arm_group_label>
    <other_name>Refresh Contacts®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adapted contact lens wearer

        Exclusion Criteria:

          -  Monovision lens wearer, ocular or systemic disease, pregnant or planning to become
             pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Chair</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2008</study_first_submitted>
  <study_first_submitted_qc>June 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2008</study_first_posted>
  <results_first_submitted>November 6, 2009</results_first_submitted>
  <results_first_submitted_qc>November 6, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 10, 2009</results_first_posted>
  <last_update_submitted>June 26, 2015</last_update_submitted>
  <last_update_submitted_qc>June 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2015</last_update_posted>
  <responsible_party>
    <name_title>Therapeutic Area Head</name_title>
    <organization>Allergan</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycerol</mesh_term>
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Carboxymethylcellulose Sodium and Glycerin</title>
          <description>Carboxymethylcellulose sodium and Glycerin based rewetting drop</description>
        </group>
        <group group_id="P2">
          <title>Carboxymethylcellulose Sodium</title>
          <description>Carboxymethylcellulose sodium based rewetting drop</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Carboxymethylcellulose Sodium and Glycerin</title>
          <description>Carboxymethylcellulose sodium and Glycerin based rewetting drop</description>
        </group>
        <group group_id="B2">
          <title>Carboxymethylcellulose Sodium</title>
          <description>Carboxymethylcellulose sodium based rewetting drop</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="166"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="246"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.6" spread="11.94"/>
                    <measurement group_id="B2" value="36.8" spread="11.54"/>
                    <measurement group_id="B3" value="37.4" spread="11.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Best Corrected Visual Acuity</title>
        <description>Percentage of Subjects Tabulated by Changes in Line Number at Day 90 from Baseline; Visual Acuity measured by LogMar reported as Snellen equivalents. Better: an increase of 2 lines or more in at least one eye; No Change: a change less than +/- 2 lines in both eyes; Worse: a decrease of 2 lines or more in at least one eye.</description>
        <time_frame>Change from Baseline at Day 90</time_frame>
        <population>Completed Population</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose Sodium and Glycerin</title>
            <description>Carboxymethylcellulose sodium and Glycerin based rewetting drop</description>
          </group>
          <group group_id="O2">
            <title>Carboxymethylcellulose Sodium</title>
            <description>Carboxymethylcellulose sodium based rewetting drop</description>
          </group>
        </group_list>
        <measure>
          <title>Best Corrected Visual Acuity</title>
          <description>Percentage of Subjects Tabulated by Changes in Line Number at Day 90 from Baseline; Visual Acuity measured by LogMar reported as Snellen equivalents. Better: an increase of 2 lines or more in at least one eye; No Change: a change less than +/- 2 lines in both eyes; Worse: a decrease of 2 lines or more in at least one eye.</description>
          <population>Completed Population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65"/>
                    <measurement group_id="O2" value="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.06"/>
                    <measurement group_id="O2" value="98.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Patient Acceptability</title>
        <description>A questionnaire was administered to all patients to evaluate the acceptability of the Rewetting Drops (RD) with use with Contact Lenses (CL). Table below shows the percentage of participants responding either &quot;Agree&quot; or &quot;Strongly Agree&quot; at day 90. Number of participants answering question is indicated as (number of Test subjects/number of Control subjects)</description>
        <time_frame>Day 90</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose Sodium and Glycerin</title>
            <description>Carboxymethylcellulose sodium and Glycerin based rewetting drop</description>
          </group>
          <group group_id="O2">
            <title>Carboxymethylcellulose Sodium</title>
            <description>Carboxymethylcellulose sodium based rewetting drop</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Acceptability</title>
          <description>A questionnaire was administered to all patients to evaluate the acceptability of the Rewetting Drops (RD) with use with Contact Lenses (CL). Table below shows the percentage of participants responding either &quot;Agree&quot; or &quot;Strongly Agree&quot; at day 90. Number of participants answering question is indicated as (number of Test subjects/number of Control subjects)</description>
          <population>Intent to Treat Population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Liked using the RD (160/78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5"/>
                    <measurement group_id="O2" value="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RD gave good comfort during day (161/79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.8"/>
                    <measurement group_id="O2" value="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RD on CL gave good initial comfort (161/79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0"/>
                    <measurement group_id="O2" value="54.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At day's end,CL felt better after RD use (161/78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.6"/>
                    <measurement group_id="O2" value="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Could wear CL longer when using RD (161/79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.6"/>
                    <measurement group_id="O2" value="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vision was normal soon after using RD (161/79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                    <measurement group_id="O2" value="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vision with CL was better after RD use (161/79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0"/>
                    <measurement group_id="O2" value="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Would likely purchase these RD (161/79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.4"/>
                    <measurement group_id="O2" value="68.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eyes felt better after CL removal (161/79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5"/>
                    <measurement group_id="O2" value="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corneal Staining</title>
        <description>Corneal staining of greater or equal to grade 2 at day 90. Grading scale: 0 = None Present; 1 = Trace Finding; 2 = Mild Finding; 3 = Moderate Finding; 4 = Severe Finding</description>
        <time_frame>Day 90</time_frame>
        <population>Completed Population</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose Sodium and Glycerin</title>
            <description>Carboxymethylcellulose sodium and Glycerin based rewetting drop</description>
          </group>
          <group group_id="O2">
            <title>Carboxymethylcellulose Sodium</title>
            <description>Carboxymethylcellulose sodium based rewetting drop</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Staining</title>
          <description>Corneal staining of greater or equal to grade 2 at day 90. Grading scale: 0 = None Present; 1 = Trace Finding; 2 = Mild Finding; 3 = Moderate Finding; 4 = Severe Finding</description>
          <population>Completed Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Patient Preference</title>
        <description>Percentage of patients who used pre-study rewetting drops and answered “Agree” or “Strongly Agree” when asked if they preferred the study drops (SD) over their pre-study drops(PSD).</description>
        <time_frame>Day 30</time_frame>
        <population>Responders Completed Population</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose Sodium and Glycerin</title>
            <description>Carboxymethylcellulose sodium and Glycerin based rewetting drop</description>
          </group>
          <group group_id="O2">
            <title>Carboxymethylcellulose Sodium</title>
            <description>Carboxymethylcellulose sodium based rewetting drop</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Preference</title>
          <description>Percentage of patients who used pre-study rewetting drops and answered “Agree” or “Strongly Agree” when asked if they preferred the study drops (SD) over their pre-study drops(PSD).</description>
          <population>Responders Completed Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prefer SD over PSD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2"/>
                    <measurement group_id="O2" value="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD more comfortable overall than PSD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2"/>
                    <measurement group_id="O2" value="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Carboxymethylcellulose Sodium and Glycerin</title>
          <description>Carboxymethylcellulose sodium and Glycerin based rewetting drop</description>
        </group>
        <group group_id="E2">
          <title>Carboxymethylcellulose Sodium</title>
          <description>Carboxymethylcellulose sodium based rewetting drop</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Conjunctival oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Episcleritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Limbal hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 90 days from the time submitted to the sponsor for review.
The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan, Inc.</organization>
      <phone>(714)246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

